Clinical Trials Logo

Xeroderma Pigmentosum clinical trials

View clinical trials related to Xeroderma Pigmentosum.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05484570 Recruiting - Clinical trials for Xeroderma Pigmentosum

Natural History Study for DNA Repair Disorders

Start date: October 1, 2022
Phase:
Study type: Observational

This will be a single-center, single-arm, non-interventional natural history study to evaluate the longitudinal clinical course, functional outcome measures, and candidate biomarkers for individuals with DNA repair disorders, including Cockayne syndrome (CS), xeroderma pigmentosum (XP), and trichothiodystrophy (TTD).

NCT ID: NCT05370235 Recruiting - Clinical trials for Xeroderma Pigmentosum

A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V

Start date: March 28, 2022
Phase: Phase 2
Study type: Interventional

The CUV152 study will evaluate the safety of afamelanotide in XP-C and XP-V patients, as well as the drug's ability to assist reparative processes following ultraviolet (UV) provoked DNA damage of the skin. It will assess whether SCENESSE® increases the amount of UV light needed to cause DNA damage of skin cells, as well as the extent of skin repair before and after treatment.

NCT ID: NCT05159752 Recruiting - Clinical trials for Xeroderma Pigmentosum

A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP)

Start date: October 19, 2021
Phase: Phase 2
Study type: Interventional

The CUV156 study will evaluate the safety of afamelanotide in XP-C patients, as well as the drug's ability to assist reparative processes following ultraviolet (UV) provoked DNA damage of the skin. It will assess whether SCENESSE® increases the amount of UV light needed to cause DNA damage of skin cells, as well as the extent of skin repair before and after treatment.